ArticleInternational journal of general medicine2026
Risk Prediction of Acute Kidney Injury in Patients with HBV-Related Acute-on-Chronic Liver Failure.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is a common and severe complication in patients with acute-on-chronic liver failure (ACLF), significantly increasing morbidity and mortality. Although several biomarkers have been proposed for the early detection of AKI, their routine clinical application remains limited by accessibility, cost, and inconsistent performance. Therefore, early identification of patients at high risk of AKI remains a major clinical challenge. Methods: This retrospective single-center study included patients with HBV-related ACLF. Clinical data were analyzed to identify independent risk factors for AKI, and a prediction model was developed. Model performance was assessed using ROC, calibration, and decision curve analyses, and patients were stratified according to risk. Results: Among 162 patients with HBV-related ACLF, 32 (19.8%) developed AKI. Patients who developed AKI had significantly higher baseline levels of blood urea nitrogen (BUN) and C-reactive protein (CRP). Multivariate analysis identified BUN (OR = 1.076, P = 0.022) and CRP (OR = 1.031, Conclusion: We developed a simple BUN-CRP-based model for early prediction of AKI in patients with HBV-related ACLF. The model demonstrated acceptable discrimination and calibration and may provide a practical tool for early risk stratification by integrating markers of renal dysfunction and systemic inflammation. However, external validation in larger multicenter cohorts is warranted before routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.